- Home
- ROOT vs QURE Comparison
ROOT vs QURE Comparison
Compare ROOT & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$15.65
Company Overview
Basic Information| Metric | ROOT | QURE |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 804.6M | 663.4M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ROOT | QURE |
|---|---|---|
| Price | $47.66 | $15.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $97.80 | $44.92 |
| AVG Volume (30 Days) | 357.7K | ★ 4.6M |
| Earning Date | 05-06-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.96 | ★ 29.67 |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $1,517,100,000.00 | $13,107,000.00 |
| Revenue This Year | $11.13 | $126.12 |
| Revenue Next Year | $13.29 | $210.54 |
| P/E Ratio | $19.96 | ★ N/A |
| Revenue Growth | ★ 28.95 | N/A |
| 52 Week Low | $42.65 | $7.76 |
| 52 Week High | $162.99 | $71.50 |
Technical Indicators
Market Signals| Indicator | ROOT | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 43.54 | 45.23 |
| Support Level | $42.65 | $13.35 |
| Resistance Level | $47.83 | $16.31 |
| Average True Range (ATR) | 2.05 | 1.49 |
| MACD | 0.90 | 0.36 |
| Stochastic Oscillator | 88.58 | 30.30 |
Price Performance
Historical Comparison ROOT
QURE
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.